Literature DB >> 16873275

Hydrophobic alpha-helices 1 and 2 of herpes simplex virus gH interact with lipids, and their mimetic peptides enhance virus infection and fusion.

Tatiana Gianni1, Romana Fato, Christian Bergamini, Giorgio Lenaz, Gabriella Campadelli-Fiume.   

Abstract

Entry of herpes simplex virus into cells occurs by fusion and requires four glycoproteins. gD serves as the receptor binding glycoprotein. Of the remaining glycoproteins, gH carries structural and functional elements typical of class 1 fusion glycoproteins, in particular alpha-helix 1 (alpha-H1), with properties of a candidate fusion peptide, and two heptad repeats. Here, we characterized alpha-H2 and compared it to alpha-H1. alpha-H2 (amino acids 513 to 531) is of lower hydrophobicity than alpha-H1. Its deletion or mutation decreased virus infection and cell fusion. Its replacement with heterologous fusion peptides did not rescue infection and cell fusion beyond the levels exhibited by the alpha-H2-deleted gH. This contrasts with alpha-H1, which cannot be deleted and can be functionally replaced with heterologous fusion peptides (T. Gianni et al., J. Virol. 79:2931-2940, 2005). Synthetic peptides mimicking alpha-H1 and alpha-H2 induced fusion of nude lipid vesicles. Importantly, they increased infection of herpes simplex virus, pseudorabies virus, bovine herpesvirus 1, and vesicular stomatitis virus. The alpha-H1 mimetic peptide was more effective than the alpha-H2 peptide. Consistent with the findings that gH carries membrane-interacting segments, a soluble form of gH, but not of gD or gB, partitioned with lipid vesicles. Current findings highlight that alpha-H2 is an important albeit nonessential region for virus entry and fusion. alpha-H1 and alpha-H2 share the ability to target the membrane lipids; they contribute to virus entry and fusion, possibly by destabilizing the membranes. However, alpha-H2 differs from alpha-H1 in that it is of lower hydrophobicity and cannot be replaced with heterologous fusion peptides.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16873275      PMCID: PMC1563806          DOI: 10.1128/JVI.00504-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Virus receptor arrays, CD46 and human herpesvirus 6.

Authors:  G Campadelli-Fiume
Journal:  Trends Microbiol       Date:  2000-10       Impact factor: 17.079

Review 2.  Mechanisms of viral membrane fusion and its inhibition.

Authors:  D M Eckert; P S Kim
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

3.  Sendai virus internal fusion peptide: structural and functional characterization and a plausible mode of viral entry inhibition.

Authors:  J K Ghosh; S G Peisajovich; Y Shai
Journal:  Biochemistry       Date:  2000-09-26       Impact factor: 3.162

Review 4.  The structural biology of type I viral membrane fusion.

Authors:  Peter M Colman; Michael C Lawrence
Journal:  Nat Rev Mol Cell Biol       Date:  2003-04       Impact factor: 94.444

5.  Membrane interface-interacting sequences within the ectodomain of the human immunodeficiency virus type 1 envelope glycoprotein: putative role during viral fusion.

Authors:  T Suárez; W R Gallaher; A Agirre; F M Goñi; J L Nieva
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Substitution in the murine nectin1 receptor of a single conserved amino acid at a position distal from the herpes simplex virus gD binding site confers high-affinity binding to gD.

Authors:  Laura Menotti; Rita Casadio; Carlo Bertucci; Marc Lopez; Gabriella Campadelli-Fiume
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

7.  Cell fusion induced by herpes simplex virus glycoproteins gB, gD, and gH-gL requires a gD receptor but not necessarily heparan sulfate.

Authors:  P E Pertel; A Fridberg; M L Parish; P G Spear
Journal:  Virology       Date:  2001-01-05       Impact factor: 3.616

8.  DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.

Authors:  S Rovero; A Amici; E Di Carlo; R Bei; P Nanni; E Quaglino; P Porcedda; K Boggio; A Smorlesi; P L Lollini; L Landuzzi; M P Colombo; M Giovarelli; P Musiani; G Forni
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

9.  Analysis of synthetic peptides from heptad-repeat domains of herpes simplex virus type 1 glycoproteins H and B.

Authors:  Stefania Galdiero; Mariateresa Vitiello; Marina D'Isanto; Annarita Falanga; Craig Collins; Katia Raieta; Carlo Pedone; Helena Browne; Massimiliano Galdiero
Journal:  J Gen Virol       Date:  2006-05       Impact factor: 3.891

10.  A heptad repeat in herpes simplex virus 1 gH, located downstream of the alpha-helix with attributes of a fusion peptide, is critical for virus entry and fusion.

Authors:  Tatiana Gianni; Laura Menotti; Gabriella Campadelli-Fiume
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

View more
  25 in total

1.  The herpesvirus glycoproteins B and H.L are sequentially recruited to the receptor-bound gD to effect membrane fusion at virus entry.

Authors:  Tatiana Gianni; Cristina Forghieri; Gabriella Campadelli-Fiume
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-14       Impact factor: 11.205

2.  Complexes between herpes simplex virus glycoproteins gD, gB, and gH detected in cells by complementation of split enhanced green fluorescent protein.

Authors:  Elisa Avitabile; Cristina Forghieri; Gabriella Campadelli-Fiume
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

3.  Intracellular trafficking and maturation of herpes simplex virus type 1 gB and virus egress require functional biogenesis of multivesicular bodies.

Authors:  Arianna Calistri; Paola Sette; Cristiano Salata; Enrico Cancellotti; Cristina Forghieri; Alessandra Comin; Heinrich Göttlinger; Gabriella Campadelli-Fiume; Giorgio Palù; Cristina Parolin
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

4.  Herpes simplex virus glycoprotein B associates with target membranes via its fusion loops.

Authors:  Brian P Hannah; Tina M Cairns; Florent C Bender; J Charles Whitbeck; Huan Lou; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

5.  Insertional mutations in herpes simplex virus type 1 gL identify functional domains for association with gH and for membrane fusion.

Authors:  Qing Fan; Erick Lin; Patricia G Spear
Journal:  J Virol       Date:  2009-09-02       Impact factor: 5.103

6.  Capturing the herpes simplex virus core fusion complex (gB-gH/gL) in an acidic environment.

Authors:  Tina M Cairns; J Charles Whitbeck; Huan Lou; Ekaterina E Heldwein; Tirumala K Chowdary; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

7.  Herpes simplex virus glycoproteins H/L bind to cells independently of {alpha}V{beta}3 integrin and inhibit virus entry, and their constitutive expression restricts infection.

Authors:  Tatiana Gianni; Arianna Cerretani; Rebecca Dubois; Stefano Salvioli; Scott S Blystone; Felix Rey; Gabriella Campadelli-Fiume
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

8.  Structure-based mutational analysis of the highly conserved domain IV of glycoprotein H of pseudorabies virus.

Authors:  Walter Fuchs; Marija Backovic; Barbara G Klupp; Felix A Rey; Thomas C Mettenleiter
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

9.  Insertion mutations in herpes simplex virus 1 glycoprotein H reduce cell surface expression, slow the rate of cell fusion, or abrogate functions in cell fusion and viral entry.

Authors:  Julia O Jackson; Erick Lin; Patricia G Spear; Richard Longnecker
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

10.  Herpes simplex virus gD forms distinct complexes with fusion executors gB and gH/gL in part through the C-terminal profusion domain.

Authors:  Tatiana Gianni; Michele Amasio; Gabriella Campadelli-Fiume
Journal:  J Biol Chem       Date:  2009-04-22       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.